Bayer 21343

Trial Bayer 21343
Cancer Type Miscellaneous
Hospital(s) Belfast City Hospital

An Open-Label, Phase Ib, Dose Escalation And Expansion Study To Evaluate The Safety, Tolerability, Maximum Tolerated Or Administered Dose, Pharmacokinetics, Pharmacodynamics And Efficacy Of The Aryl Hydrocarbon Receptor Inhibitor (AhRi) Bay 2416964 In Combination With Pembrolizumab In Participants With Advanced Solid Tumours

Posted in .